Barbara Kiesewetter

35PUBLICATIONS
40CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epigenetics (incl. genome methylation and epigenomics)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Aug 07, 2026
Long-term complete remission following treatment with polatuzumab vedotin, rituximab, and bendamustine in a patient with mantle cell lymphoma relapsing after CAR-T cell therapy: a case report.

|Jul 06, 2026
Oligometastatic neuroendocrine tumors: characteristics and prognosis.

|Mar 31, 2026
Patient characteristics and prognostic factors in advanced treatment lines in metastatic neuroendocrine tumors.

Philipp Melhorn, Genti Zhitia, Markus Raderer

|Mar 03, 2026
Field-testing the MALT-IPI in a single-center real-world cohort of patients with extranodal marginal zone lymphoma.

Vincent Sunder-Plassmann, Barbara Kiesewetter, Ingrid Simonitsch-Klupp

|Jun 20, 2025
Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios.

Philipp Melhorn, Elisabeth Kretschmer-Chott, Peter Mazal

|Mar 12, 2025
Methylation Profiles Differ According to Clinical Characteristics in Well-Differentiated Neuroendocrine Tumors of the Lung.

Philipp Melhorn, Erwin Tomasich, Alissa Blessing

Pageof 6

Frequent Collaborators

13 joint publications

Markus Raderer

10 joint publications

Philipp Melhorn

2 joint publications

Vincent Sunder-Plassmann

2 joint publications

Matthias Preusser